Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3858279 Evoked Pain Study
NCT04114656Phase 1Terminated
- Sponsor
- GSK
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3858279 in pain (2 arms), sponsored by GSK. Primary endpoints: Posterior Median Ratio to Baseline of Area Under the Curve in Ultraviolet B Heat Pain Detection, Posterior Median Ratio to Baseline of Area Under the Curve in Cold Pressor Time to Intolerable Pain Threshold and 1 more. Started Oct 2019; status: terminated.
02
Drugs
GSK3858279
03
Conditions
pain
Beyond the preview
Go deeper on NCT04114656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114656.